

Title (en)
METHOD OF TREATING GASTROINTESTINAL ULCERS AND COMPOSITIONS THEREFOR

Title (de)
VERFAHREN ZUR BEHANDLUNG VON MAGENDARMGESCHWÜREN UND DIE DAZUGEHÖRIGEN MITTEL

Title (fr)
PROCEDE ET COMPOSITIONS DE TRAITEMENT DES ULCERES GASTRO-INTESTINAUX

Publication
EP 1005355 A4 20020717 (EN)

Application
EP 98919780 A 19980415

Priority
• US 9807686 W 19980415
• US 4302397 P 19970415

Abstract (en)
[origin: WO9846249A1] The invention provides methods and compositions for providing chronic gastrointestinal ulcer healing or acute gastroprotection. In particular, administration of a pharmaceutically effective amount of VEGF, such as from about 30 ng/kg to about 1000 mu g/kg per day for about a week to two months results in healing of GI ulcers in a mammal, such as a human. Examples of gastrointestinal ulcers include duodenal ulcers, peptic ulcers, drug-induced ulcers, or intestinal ulcers, including but not limited to damage due to non-steroidal (NSAID) and anti-inflammatory drugs, gastro-esophogheal reflux disease or inflammatory bowel disease such as ulcerative colitis and Crohn's disease. Similarly, administration of a pharmaceutically effective amount of VEGF, such as from about 3 mu g/kg to about 1000 mu g/kg VEGF, from 0 minutes to about 60 minutes prior to potential injury to the GI tract, such as ingestion of an NSAID or ethanol, results in acute gastroprotection.

IPC 1-7
A61K 38/00; **A61K 38/19**; **A61P 1/04**

IPC 8 full level
A61K 38/19 (2006.01)

CPC (source: EP)
A61K 38/1866 (2013.01); **A61P 1/04** (2017.12)

Citation (search report)
• [XY] US 5194596 A 19930316 - TISCHER EDMUND G [US], et al
• [XY] WO 9606641 A1 19960307 - PRIZM PHARMA INC [US]
• [Y] EP 0269408 A2 19880601 - GENENTECH INC [US]
• [X] SZABO S ET AL: "Modulation of vascular factors by VEGF/VPF (vascular endothelial cell growth factor/vascular permeability factor) is sufficient for chronic ulcer healing and acute gastroprotection.", GASTROENTEROLOGY, vol. 112, no. 4 SUPPL., 1997, Digestive Disease Week and the 97th Annual Meeting of the American Gastroenterological Association; Washington, D.C., USA; May 11-14, 1997, pages A303, XP001068612, ISSN: 0016-5085
• [XY] BRYAN WILLIAMS: "Vascular permeability/vascular endothelial growth factors: a potential role in the pathogenesis and treatment of vascular diseases", VASCULAR MEDICINE, vol. 1, no. 4, 1996, pages 251 - 258, XP001070847
• [A] HULL M A ET AL: "ISOLATION AND CULTURE OF HUMAN GASTRIC ENDOTHELIAL CELLS", GASTROENTEROLOGY, SAUNDERS, PHILADELPHIA, PA., US, vol. 5, no. 111, November 1996 (1996-11-01), pages 1230 - 1240, XP001068448, ISSN: 0016-5085
• [A] FAVARD C ET AL: "PURIFICATION AND BIOLOGICAL PROPERTIES OF VASCULOTROPIN A NEW ANGIOGENIC CYTOKINE", BIOLOGY OF THE CELL, vol. 73, no. 1, 1991, pages 1 - 6, XP001070843, ISSN: 0248-4900
• See references of WO 9846249A1

Designated contracting state (EPC)
AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

DOCDB simple family (publication)
WO 9846249 A1 19981022; EP 1005355 A1 20000607; EP 1005355 A4 20020717

DOCDB simple family (application)
US 9807686 W 19980415; EP 98919780 A 19980415